UNSPSC 51383314: Diclofenac potassium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H10Cl2NO2.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4D5UA6CB4, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but more generally known as diclofenac potassium, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac potassium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13568MIG.

Most nations, for tariff and trade purposes, schedule diclofenac potassium under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC POTASSIUM remains US FDA's Preferred Term for this commodity. Diclofenac potassium bears US NLM identifiers UMLS ID C0282131 and NCI Concept Code C47983. SMILES: C1CCC(C(C1)CC(=O)[O-])NC2C(CCCC2CL)CL.[K+].

UNSPSC 51383314 Diclofenac potassium, a Commodity code, nominally covers a specific nonsteroidal anti-inflammatory drug; however, recent state and local solicitations under this code show minimal direct purchase activity for diclofenac itself. Instead, the code appears tagged across broader pharmaceutical procurement initiatives that encompass generic multi-source drugs, over-the-counter products, and emergency medical supplies. State and local governments buying under this code are procuring pharmaceuticals through cooperative purchasing arrangements, direct-to-manufacturer programs, and emergency health procurement channels. Issuing bodies include state health agencies, county health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, representing a broad categorical procurement rather than diclofenac-specific purchase. Seminole County, Florida issued an IFB in June 2026 for emergency medical supplies (naloxone and drug deactivation systems) with a July 26, 2023 response date, though this procurement falls outside the nominal scope of a diclofenac code and suggests potential tagging misalignment.

Geographic activity centers on Minnesota and Florida, with multistate participation through cooperative purchasing vehicles. The Texas Health and Human Services Commission issued a Request for Information in April 2026 on direct-to-manufacturer prescription programs, signaling state-level interest in pharmaceutical procurement restructuring. The MMCAP procurement explicitly includes Oregon participation alongside Minnesota state and local facilities. Recent opportunities focus on establishing framework agreements with authorized pharmaceutical wholesalers, compliance with FDA cGMP and Drug Supply Chain Security Act requirements, and pricing models based on net pricing or WAC-minus structures. The mismatch between the code's nominal scope (a single NSAID product) and the actual procurement activity (broad multi-product pharmaceutical frameworks and emergency supplies) suggests this code is used inconsistently or serves as a catch-all classification for pharmaceutical purchases across state and local jurisdictions.